At 10.1% CAGR, Asia Pacific Organ Preservation Solution Market is Projected to be worth US$ 81,199.78 thousand by 2031, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific organ preservation solution market was valued at US$ 37,978.81 thousand in 2023 and is expected to reach US$ 81,199.78 thousand by 2031, registering a CAGR of 10.1% from 2023 to 2031. Strategic initiatives by market players and rising need for organ transplantation are among the critical factors attributed to drive the Asia Pacific organ preservation solution market growth.

Chronic diseases, which may be congenital or acquired, can lead to gradual damage to organs over time. A chronic disease typically does not resolve on its own, but there may be ways to slow down the damage caused by the condition. It may take decades for this damage to build up to the point where it noticeably affects patients' organ function or requires medical intervention. Chronic kidney disease (CKD) is a common and potentially fatal condition that affects approximately 1 in every 10 people worldwide.

Chronic liver diseases such as fatty liver disease and hepatitis C are the common causes of chronic liver failure. The World Health Organization (WHO) estimates that ~50 million people are living with chronic hepatitis C virus infection worldwide, with approximately 1.0 million new infections occurring each year. In 2022, ~242,000 people died from hepatitis C, mainly due to cirrhosis and hepatocellular carcinoma. Chronic heart diseases, including coronary artery disease and congenital heart disease, can lead to progressive heart failure. According to the Global Heart & Circulatory Diseases Factsheet by the British Heart Foundation, congenital heart disease is a rapidly emerging problem in child health worldwide. It is diagnosed in approximately 1 in 110 births globally, and the diagnoses later in the lives of babies may reach as high as 1.2 million per year, averaging 3,300 per day (or a diagnosis every 26 seconds). Thus, the demand for organ preservation solutions increases with a surge in the need for availability of chronic disease-related organ transplantation procedures.

On the contrary, the expensive organ transplant surgeries hamper the growth of Asia Pacific organ preservation solution market.

Based on product, the Asia Pacific organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, Hypothermosol, and others. The University of Wisconsin segment held 39.9% market share in 2023, amassing US$ 15,153.95 thousand. It is projected to garner US$ 32,462.87 thousand by 2031 to register 10.1% CAGR during 2023-2031.

In terms of application, the Asia Pacific organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held 45.8% share of Asia Pacific organ preservation solution market in 2023, amassing US$ 17,392.38 thousand. It is anticipated to garner US$ 37,883.02 thousand by 2031 to expand at 10.3% CAGR during 2023-2031.

By type, the Asia Pacific organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held 59.3% share of Asia Pacific organ preservation solution market in 2023, amassing US$ 22,521.94 thousand. It is projected to garner US$ 49,009.40 thousand by 2031 to expand at 10.3% CAGR from 2023 to 2031.

Based on end user, the Asia Pacific organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held 54.5% share of Asia Pacific organ preservation solution market in 2023, amassing US$ 20,713.30 thousand. It is predicted to garner US$ 45,171.97 thousand by 2031 to expand at 10.3% CAGR between 2023 and 2031.

Based on country, the Asia Pacific organ preservation solution market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 31.4% share of Asia Pacific organ preservation solution market in 2023. It was assessed at US$ 11,930.00 thousand in 2023 and is likely to hit US$ 26,205.32 thousand by 2031, registering a CAGR of 10.4% during 2023-2031.

Key players operating in the Asia Pacific organ preservation solution market are XVIVO Perfusion, TransMedics, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, and Shanghai Genext Pharmaceutical Technology., among others.

• In June 2019, TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage.
• In April 2018, TransMedics, Inc. Received FDA Pre-Market Approval (PMA) for its OCS Lung System for Near-Physiologic Preservation and Assessment of Lungs for Transplantation.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com